Clinical Trials Logo

Psychomotor Agitation clinical trials

View clinical trials related to Psychomotor Agitation.

Filter by:

NCT ID: NCT00371059 Completed - DEMENTIA Clinical Trials

Memantine for Agitation in Dementia

MAGD
Start date: September 2007
Phase: Phase 4
Study type: Interventional

We plan to evaluate the use of memantine in Alzheimer's disease to control agitation in the acute situation i.e under 12 weeks

NCT ID: NCT00369577 Completed - Schizophrenia Clinical Trials

Staccato Loxapine in Agitation (Proof of Concept)

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients. The study will be conducted in 120 agitated schizophrenic patients - either newly admitted to a hospital setting or a research unit for acute agitation or already in hospital for chronic underlying conditions. Patients meeting entry criteria will be randomized to one of two doses of Staccato Loxapine or to Staccato Placebo. Following administration of study drug, assessment of agitation state will be conducted at serial time points using standard agitation scales over a 24 hour period.

NCT ID: NCT00367822 Completed - Clinical trials for Restless Legs Syndrome

Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)

Start date: n/a
Phase: Phase 3
Study type: Interventional

The objective of this trial is to compare an individually optimized dose of the lisuride TTS patch against placebo and against an individually optimized dose of oral ropinirole (active- and placebo-controlled design) in idiopathic and uremic RLS patients with regard to efficacy, safety, and quality of life.

NCT ID: NCT00365352 Completed - Clinical trials for Restless Legs Syndrome

XP13512 vs. Placebo in Patients With Restless Legs Syndrome.

Start date: August 2006
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).

NCT ID: NCT00363857 Completed - Clinical trials for Restless Legs Syndrome

A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome

Start date: August 2003
Phase: Phase 3
Study type: Interventional

A 14-Week clinical research study to compare the effectiveness and safety of ropinirole and placebo (an inactive sugar pill) in the treatment of patients with Restless Legs Syndrome (RLS) in the United States.

NCT ID: NCT00357097 Completed - Clinical trials for Restless Legs Syndrome

The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome

Start date: June 2006
Phase: Phase 3
Study type: Interventional

Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no therapy to know whether a drug could improve both depressive and RLS symptoms.

NCT ID: NCT00356096 Completed - Depression Clinical Trials

Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances

Start date: July 2006
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to determine the efficacy of pramipexole 0.125 mg to 0.75 mg daily versus placebo on RLS symptoms and on associated mood disturbances and depressive symptoms, after 12 weeks of treatment

NCT ID: NCT00355641 Completed - Clinical trials for Restless Legs Syndrome

Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of ropinirole XR in the long-term treatment (up to 52 weeks)of adults with RLS.

NCT ID: NCT00349531 Completed - Clinical trials for Restless Legs Syndrome

A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS

Start date: July 2006
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to investigate the effects on RLS symptoms and sleep disturbance of pramipexole (Mirapexin) 0.125 mg/day to 0.75 mg/day per os for 12 weeks, compared to placebo, in the treatment of patients with idiopathic Restless Legs Syndrome

NCT ID: NCT00344994 Completed - Clinical trials for Restless Legs Syndrome

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

Start date: May 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the equipotent dose of ropinirole and pramipexole for patients switched from pramipexole to ropinirole in patients with moderate to severe primary Restless Legs Syndrome (RLS). The rationale behind Switch is that patients with Restless Legs Syndrome can maintain stable efficacy and tolerability if correctly switched from one dopamine agonist to an equipotent dose of another.